The research team focused on a well-established mouse model of lung adenocarcinoma driven by mutations in the Kras and Trp53 genes, a system that closely recapitulates the progression of human non-small-cell lung cancer. In this model, known as KP-Tracer, cancer cells carry heritable molecular barcodes that accumulate edits as cells divide, allowing researchers to reconstruct family trees of tumor cells long after the fact. By reading out these barcodes alongside genome-wide gene expression, the team could infer not only which cells were related to one another but also where they sat within the tumor and what molecular programs they were running.

Technically, the platform integrates two complementary spatial assays. Slide-seq provides genome-wide expression measurements on dense arrays of bead-based spots at near-cellular resolution across entire tissue sections, while Slide-tags assigns spatial coordinates to individual cell nuclei, enabling single-cell profiling with positional information. The lineage barcodes embedded in the tumor cells could be captured in both assays, though with substantial dropout and missing data. To address this, the team developed computational methods, including spatial imputation strategies that borrow lineage information from neighboring spots, and benchmarked their phylogeny-reconstruction pipelines extensively on simulated data to ensure that the inferred evolutionary trees were robust to the noise inherent in spatial measurements.

With this integrated platform in hand, the researchers asked a fundamental question: where within a tumor does expansion actually happen, and what does the microenvironment look like in those regions? By combining the reconstructed phylogenies with spatial maps, an approach the authors describe as tumor phylogeography, they identified regions of recent subclonal expansion, essentially the growing edges of the tumor’s family tree. These expanding subclones were not randomly distributed. Instead, they were consistently associated with a distinctive microenvironmental signature: hypoxia, fibrosis and immunosuppression.

The association was striking. Areas harboring rapidly expanding subclones were enriched for low-oxygen conditions, marked by expression of hypoxia-response genes such as the glucose transporter GLUT1. They also contained dense deposits of extracellular matrix produced by activated fibroblasts and were populated by immunosuppressive immune cells, including Arg1-expressing tumor-associated macrophages. In other words, the most successful cancer clones were not simply the ones with the best intrinsic growth programs; they were the ones that had managed to engineer, or at least exploit, a microenvironment that suppressed immune attack and supplied the conditions for aggressive proliferation.

To disentangle cause from correlation, the team turned to controlled experiments. Using organoid co-culture systems, they exposed cancer cells to hypoxic conditions and to specific stromal cell partners, testing how these extrinsic factors influenced cancer cell state. The results supported a model in which hypoxia and intercellular signaling integrate to push cancer cells toward prometastatic, high-plasticity states, including epithelial-to-mesenchymal transition-like programs previously linked to metastatic competence. Spatially aware ligand-receptor analysis, performed with a purpose-built algorithm called LARIS, further revealed that the rewired interactions between macrophages, fibroblasts and cancer cells in expanding niches differed markedly from those in non-expanding regions, pinpointing candidate signaling pathways that sustain the aggressive state.

Perhaps the most consequential findings concern metastasis. By tracing lineage barcodes from primary tumors into metastatic lesions found in lymph nodes, the diaphragm and other sites, the researchers showed that metastases arise from spatially confined subclones within the primary tumor rather than from cells scattered broadly across it. The metastasis-seeding subclones occupied identifiable niches at the primary site, and their genealogical signatures could be detected across serial tissue sections, effectively allowing the team to watch the metastatic cascade unfold backward from the established lesion to its birthplace in the primary tumor.

Equally important, the study found that metastases do not merely inherit traits from their parent clones; they actively remodel the distant sites they colonize. Metastatic lesions, and even the pre-metastatic neighborhoods surrounding them, became fibrotic and collagen-rich, with elevated TGF-beta signaling. The team extended this observation to human disease by analyzing single-cell data from a pan-cancer atlas of human brain metastases and spatial transcriptomics datasets of human non-small-cell lung cancer, finding that collagen deposition, TGF-beta activity and hypoxia signatures were similarly elevated in human metastatic compartments. This convergence between the mouse model and human data strengthens the case that the mechanisms uncovered are not artifacts of the experimental system.

The implications for cancer medicine are substantial. If prometastatic cell states emerge specifically within hypoxic, fibrotic and immunosuppressive niches, then targeting the microenvironment, for example by alleviating hypoxia, modulating fibroblast activity or reprogramming suppressive macrophages, could potentially prevent the emergence of metastatic competence before it arises. The findings also suggest that sampling strategies in the clinic, which often rely on a single biopsy, may miss the spatially restricted subclones that matter most for a patient’s prognosis. Understanding where within a tumor the dangerous clones reside could inform how biopsies are taken and how risk is assessed.

The study also represents a methodological milestone for the field of spatial lineage tracing. The authors have released their processed data via Zenodo, deposited raw sequencing data under a public BioProject accession, and made their analysis code, including the Cassiopeia lineage-reconstruction framework and spatial analysis notebooks, freely available on GitHub under an open license. As these tools proliferate, the ability to read a tumor’s history directly from its architecture may become a standard part of the cancer biologist’s toolkit, transforming how researchers study not only lung cancer but the evolutionary dynamics of malignancies throughout the body.

Subject of Research: Spatiotemporal lineage tracing of lung adenocarcinoma to map tumor growth, microenvironmental remodeling and metastasis

Article Title: Spatiotemporal lineage tracing reveals the dynamic spatial architecture of tumor growth and metastasis

Article References: Jones, M. G., Sun, D., Min, K. H. J., Colgan, W. N., Wang, H., Török, T., Ribeiro, J., Xue, J., Cardoso, E. C., Rong, Y., Tian, L., Weir, J. A., Chen, V. Z., Koblan, L. W., Yost, K. E., Mathey-Andrews, N., D’Souza, E., Russell, A. J. C., Stickels, R. R., … Yang, D. (2026). Spatiotemporal lineage tracing reveals the dynamic spatial architecture of tumor growth and metastasis. Nature Genetics, 58(9), 2398-2410. https://doi.org/10.1038/s41588-026-02739-z

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02739-z

Keywords: lineage tracing, spatial transcriptomics, tumor evolution, lung adenocarcinoma, tumor microenvironment, metastasis, hypoxia, fibrosis, immunosuppression, tumor phylogeography, Slide-seq, Slide-tags

Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, is often described as a genetically complex and highly heterogeneous disease. Heterogeneity means that cancer cells within the same tumour may carry different molecular programs, use different nutrients, interact differently with surrounding tissues and respond differently to chemotherapy or targeted drugs. Two broad transcriptional identities have attracted particular attention. Classical tumour cells generally retain features associated with more differentiated pancreatic epithelial cells and can display gene programs linked to secretory or epithelial functions. Basal-like cells, in contrast, are typically associated with a more aggressive state, altered cellular architecture, enhanced stress responses and poorer clinical outcomes. These categories are not rigid boxes; cancer cells can shift between states as their environment changes. Reproducing that flexibility outside the body has been one of the central difficulties in pancreatic cancer research.

Organoids are three-dimensional cell cultures that grow from tumour tissue and self-organise into structures that preserve some features of the original cancer. Unlike conventional two-dimensional cell lines, organoids can maintain cell-to-cell contacts, three-dimensional architecture and, in many cases, a portion of the genetic and phenotypic diversity found in a patient’s tumour. However, organoids are also shaped by the conditions in which they are grown. Oxygen is one of the most influential variables. Tumours are not uniformly supplied with oxygen: blood vessels are unevenly distributed, and rapidly dividing cells can consume oxygen faster than it can be delivered. This creates local oxygen gradients, with relatively oxygen-rich regions existing beside hypoxic zones. Such gradients can alter metabolism, activate stress pathways and influence which genes cancer cells express. The study’s dual-oxygen strategy addresses this environmental factor directly rather than treating oxygen as a fixed background condition.

According to the report, pancreatic cancer organoids exposed to distinct oxygen conditions reproduced molecular features corresponding to both basal and classical tumour states. This observation is important because it suggests that the model does not merely preserve a static genetic identity inherited from the tumour sample. Instead, it can reveal how environmental context helps shape cellular behaviour. Oxygen availability can influence the activity of transcription factors that regulate adaptation to low oxygen, including pathways controlled by hypoxia-inducible factors. It can also affect mitochondrial respiration, glycolysis, redox balance and the production of metabolites that serve as signals inside the cell. These changes may, in turn, remodel gene expression and push tumour cells toward distinct phenotypic programs. By generating organoids under two oxygen regimes, the researchers created a controllable way to examine this interaction between the cancer genome and its surroundings.

The study’s central claim was strengthened through spatial transcriptomics, which provides a type of molecular map rather than a simple list of active genes. In conventional RNA sequencing, tissue is often broken apart before analysis, meaning that information about each cell’s original position is largely lost. Spatial transcriptomics retains the physical coordinates of gene expression, allowing researchers to ask whether particular transcriptional programs are concentrated in specific regions or associated with neighbouring cell populations. This distinction matters in pancreatic cancer, where tumour cells, fibroblasts, immune cells, blood vessels and extracellular matrix form tightly interwoven microenvironments. By comparing the organoid-derived signatures with spatially resolved patterns in tumour tissue, the investigators were able to test whether the basal–classical diversity observed in culture corresponded to structures found in real cancers.

The validation does not mean that an organoid is a complete miniature pancreas or a perfect replica of a patient’s tumour. Organoid cultures generally lack the full immune system, blood circulation, nerve supply and complex stromal architecture present in living tissue. Culture media can also select for particular cell populations, while prolonged propagation may gradually favour clones that grow best under laboratory conditions. These limitations are especially relevant when studying oxygen, because real tumours experience constantly changing gradients rather than two neatly separated experimental environments. Even so, the agreement between the dual-oxygen organoid model and spatial transcriptomic patterns provides evidence that oxygen-sensitive tumour states are not simply artefacts of a dish. It indicates that the model captures at least one biologically meaningful layer of pancreatic cancer organisation.

The implications extend beyond classification. If basal and classical states can be influenced by oxygen and other microenvironmental signals, then treatment resistance may emerge not only from permanent mutations but also from reversible changes in cell identity. A tumour cell that appears relatively differentiated under one condition could adopt a more basal-like, stress-tolerant program under another. Such plasticity may help cancer survive chemotherapy, evade immune attack or repopulate a tumour after treatment. Dual-oxygen organoids could allow researchers to expose matched cancer models to drugs while monitoring whether treatment eliminates a particular state, encourages a transition into another state or leaves behind a resistant population. The system may also support studies of combination therapies designed to target both cancer-cell-intrinsic pathways and the environmental signals that maintain aggressive phenotypes.

The work arrives as cancer researchers increasingly move away from the idea that a tumour can be understood from DNA mutations alone. Genomic alterations remain fundamental, but they operate within a living ecosystem in which oxygen, nutrients, mechanical forces and neighbouring cells continuously shape tumour behaviour. By linking three-dimensional culture, controlled oxygen exposure and spatial transcriptomics, the Japanese research team offers a framework for studying that ecosystem with greater precision. The model could help explain why samples carrying similar mutations develop different clinical courses and why a therapy that works in one region of a tumour may fail in another. Further studies will need to determine how stable the induced states are, how closely they predict patient responses and whether immune or stromal components can be incorporated without losing experimental control. For now, the findings highlight a powerful message: in pancreatic cancer, where a cell grows may be almost as important as the mutations it carries.

Subject of Research: Pancreatic cancer heterogeneity, oxygen-dependent tumour states, cancer organoids and spatial transcriptomics

Article Title: Dual-oxygen pancreatic cancer organoids recapitulate basal–classical heterogeneity validated by spatial transcriptomics

Article References: Kumano, K., Nakahashi, H., Shimomura, O. et al. “Dual-oxygen pancreatic cancer organoids recapitulate basal–classical heterogeneity validated by spatial transcriptomics.” British Journal of Cancer (2026). https://doi.org/10.1038/s41416-026-03577-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41416-026-03577-w

Keywords: pancreatic cancer, cancer organoids, tumour heterogeneity, basal-like subtype, classical subtype, oxygen tension, hypoxia, spatial transcriptomics, tumour microenvironment, precision oncology

The work addresses a central problem in cancer biology: molecular behavior observed in cultured cells or isolated tumor samples may not accurately reflect what happens in vivo. Within the brain, glioblastoma cells encounter a complex environment formed by neurons, astrocytes, blood vessels, immune cells and extracellular matrix components. These neighboring cells and structures can deliver biochemical signals that alter tumor-cell survival, movement, metabolism and resistance to therapy. Mapping those interactions in their natural setting is therefore essential for understanding why glioblastoma remains so difficult to control.

Disseminated glioblastoma cells are particularly challenging to study because they may be sparse, spatially separated from the main tumor mass and biologically distinct from cells at the tumor core. A cell that has migrated through brain tissue may activate different receptors, transcription factors and stress-response pathways from those used by a rapidly dividing cell within the original lesion. Such differences can create clinically important subpopulations that are missed when researchers analyze the tumor as a single, uniform entity.

INSIGHT is presented as a strategy for uncovering these in vivo signaling networks. In technical terms, signaling networks are interconnected systems in which extracellular cues activate membrane receptors, intracellular enzymes and transcriptional regulators, ultimately changing gene expression and cellular behavior. Rather than treating these pathways as isolated linear chains, network-based analysis examines how multiple signals converge, reinforce one another or become rewired as tumor cells move through different microenvironments. This perspective can reveal why blocking one pathway may produce only a temporary response while alternative routes remain active.

The significance of the study lies in its focus on disseminated cells rather than only on the dominant tumor population. Glioblastoma progression is shaped by cellular plasticity, the ability of malignant cells to change state in response to local conditions. A disseminated cell may adopt a more invasive phenotype, enter a relatively dormant condition or activate mechanisms that help it withstand therapeutic pressure. Detecting the signals associated with these transitions could help researchers distinguish processes that merely accompany dissemination from those that actively drive it.

A major challenge in this field is preserving the biological context in which signaling occurs. Removing cells from the brain can interrupt short-lived molecular interactions, alter nutrient and oxygen conditions, and eliminate signals supplied by surrounding tissues. An in vivo platform such as INSIGHT is consequently important because it is designed to examine signaling behavior under physiological conditions, where the timing, location and intensity of molecular cues can influence the fate of individual cancer cells. These measurements may provide a more realistic picture of tumor evolution than conventional endpoint analyses.

The research also has implications for the development of precision therapies. If disseminated glioblastoma cells rely on a distinct combination of signaling pathways, effective treatment may require targeting network vulnerabilities rather than a single molecular switch. Researchers could use such information to identify pathway combinations, determine which signals are associated with invasion or survival, and prioritize biomarkers that predict treatment response. The approach may also help explain why therapies that shrink the primary tumor do not always prevent recurrence elsewhere in the brain.

Although the study centers on glioblastoma, its conceptual value may extend beyond neuro-oncology. Many cancers spread by adapting to new tissue environments, and metastatic cells frequently display molecular states that differ from those of the original tumor. A method capable of linking the location of disseminated cells with their active signaling programs could therefore support investigations of metastasis in other organs. The ability to study cancer cells in living systems may be especially valuable for identifying transient states that disappear during tissue processing or laboratory culture.

The findings underscore a broader shift in cancer research toward dynamic, spatially resolved biology. Tumors are not static masses but evolving ecosystems in which malignant cells continuously interpret signals from their surroundings. By applying INSIGHT to disseminated glioblastoma cells in vivo, Ahn and colleagues aim to illuminate the molecular conversations that enable these cells to survive and spread through the brain. The resulting network maps could provide a foundation for future experiments, biomarker discovery and therapeutic strategies designed to target the most dangerous cellular states before they become the source of recurrent disease.

Subject of Research: Signaling networks of disseminated glioblastoma cells in vivo

Article Title: Uncovering the signaling networks of disseminated glioblastoma cells in vivo with INSIGHT

Article References: Ahn, R., D’Souza, A.D., Long, L. et al. “Uncovering the signaling networks of disseminated glioblastoma cells in vivo with INSIGHT.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76587-0

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76587-0

Keywords: Glioblastoma, cancer dissemination, in vivo signaling, tumor microenvironment, cellular plasticity, cancer biology, INSIGHT, brain tumors

A collaborative team from the European Molecular Biology Laboratory (EMBL), Heinrich Heine University Düsseldorf (HHU), and University Hospital Düsseldorf (UKD) has introduced spatialproteomics, an open-source software package aimed at simplifying analysis of highly multiplexed tissue imaging. The work appears in Nature Methods.

Multiplexed fluorescence imaging can label dozens of molecular markers while preserving where each cell sits in a tissue section. With this capability, researchers can survey thousands to millions of cells and map the tumor microenvironment with far greater depth than conventional pathology. The payoff is an unprecedented view of protein distributions across cell types and microanatomical structures.

The challenge begins after imaging. Before spatial relationships can be assessed, investigators must segment cells, identify and annotate them, and quantify protein signals across massive datasets. Historically, these tasks often required stitching together multiple tools and custom pipelines, reducing reproducibility and raising barriers for new users.

Spatialproteomics addresses these steps within a single interoperable workflow, guiding users from raw microscopy inputs through segmentation, annotation, and spatial analysis. By standardizing the computational route from image to metric, the software is designed to make results more consistent across studies and more scalable to large cohorts.

To validate the framework, the team analyzed patient samples from B-cell non-Hodgkin lymphoma. The software enabled systematic characterization of how proteins distribute across tumor and immune compartments, revealing distinct spatial patterns tied to disease biology. These computational signatures helped differentiate indolent, slow-growing lymphomas from more aggressive forms.

The study also underscores a broader shift in biomedical imaging: as technologies generate richer spatial data, the limiting factor moves toward accessible, robust analysis software. By lowering technical hurdles and emphasizing reproducible workflows, spatialproteomics supports wider adoption of spatially resolved proteomic insights.

Because lymphoma is only one application, the authors anticipate benefits across many areas of biomedical research, including other cancers and inflammatory disorders where tissue organization is central to outcome.

Subject of Research: Spatial organization of tumor and immune microenvironments in B-cell non-Hodgkin lymphoma using multiplexed fluorescence imaging and spatial proteomics analysis.
Article Title: Spatialproteomics: an interoperable toolbox for analyzing highly multiplexed fluorescence image data
News Publication Date: 24-Jul-2026
Web References: http://dx.doi.org/10.1038/s41592-026-03155-1
References: Nature Methods (published article)
Image Credits: UKD
Keywords: Cancer; Proteomics; Genomics; Imaging; Lymphoma

In the study, the platform was expanded to include fibroblasts, cells previously linked to immunotherapy resistance in liver cancer. Using a machine-learning calibration workflow, the model was tuned to data from real clinical trials, producing “virtual patients” whose predicted outcomes can be compared with observed responses.

The key advance is spatial modeling. By tracking where individual cell populations reside, the researchers map the tumor microenvironment architecture that governs treatment sensitivity. This includes the distribution and organization of fibroblasts, immune T cells, and cancer cells, revealing how physical and biochemical barriers can shape drug effectiveness.

The team tested the system against therapy scenarios involving cabozantinib, a targeted therapy that blocks tumor growth signaling, and nivolumab, an immunotherapy. Simulated response rates aligned closely with those reported in clinical trials, suggesting the virtual cohort behaves like real patients.

To validate biological realism, the researchers compared predicted tumor architectures with post-treatment tissue patterns. They also contrasted the microenvironments of responders and non-responders, identifying mechanisms tied to therapeutic failure.

A striking finding emerged in predicted non-responders: fibroblasts can remodel the microenvironment into an immunosuppressive structure. In simulations, fibroblasts assemble into a physical “wall” that prevents T cells from reaching tumor regions, even when immune cells are nearby.

Because architectural features are visible before therapy begins, the model could help stratify patients—flagging who is likely to respond and who might need alternative strategies. The framework is intended for future clinical validation, rather than immediate use in treatment decisions.

The work was supported by multiple funding sources including the National Institutes of Health and other agencies. Results were published online July 14 in the Proceedings of the National Academy of Sciences.

Subject of Research: Predicting immunotherapy benefit in hepatocellular carcinoma using spatial computational modeling
Article Title: (Not provided in the provided content)
News Publication Date: July 14
Web References: https://www.pnas.org/doi/10.1073/pnas.2525799123
References: Proceedings of the National Academy of Sciences (PNAS), published online July 14
Image Credits: Atul Deshpande, Ph.D., and colleagues

Keywords: hepatocellular carcinoma, immunotherapy, cabozantinib, nivolumab, quantitative systems pharmacology, agent-based modeling, tumor microenvironment, fibroblasts, predictive modeling, virtual patients

Tumors are not monolithic masses but highly heterogeneous and spatially organized entities. Within these three-dimensional structures, a myriad of cell types, including malignant cells, stromal elements, immune cells, and vascular components, co-exist and interact in a tightly choreographed yet chaotic manner. This complex web of interactions governs the tumor’s behavior—its growth, progression, potential to invade surrounding tissues, and capability to metastasize. Historically, studies have examined tumors largely through dissociated cells or thin tissue sections, providing snapshots that fail to capture the holistic spatial context of tumor microenvironments and their evolution.

The emergence of spatial multi-omics technologies is revolutionizing this landscape by integrating genomic, transcriptomic, proteomic, and metabolomic data with spatial resolution. By preserving the architectural integrity of tumor tissues, scientists can now map molecular profiles directly onto three-dimensional landscapes. This progression is pivotal because cellular function and fate are often dictated not merely by intrinsic properties but by their spatial context and interaction with neighboring cells and extracellular matrices. The ability to visualize where, when, and how molecular signals propagate within tumors offers unprecedented insights into cancer biology that were previously inaccessible.

Creating 3D tumor atlases entails the integration of these spatially resolved multi-omics data, producing comprehensive maps that delineate tumor cell populations, stromal niches, vascular networks, and immune infiltrates within intact tissue volumes. Such atlases are dynamic, capable of capturing temporal changes across tumor initiation, progression, and metastasis. They enable researchers to track the evolutionary trajectories of cancer cells and their interactions with the microenvironment over time, thus shedding light on the operational principles that govern tumor heterogeneity and adaptation.

An extraordinary challenge in this domain is the sheer scale and complexity of the data generated. Sophisticated computational tools and machine learning algorithms are indispensable for data integration, visualization, and interpretation. These technologies facilitate the reconstruction of high-resolution 3D tumor models and the identification of spatially restricted molecular signatures that could serve as novel biomarkers. Furthermore, this computational prowess enables the dissection of intricate cellular crosstalk, revealing potential vulnerabilities in tumor ecosystems that might be exploited therapeutically.

Among the promising applications of 3D tumor atlases is their role in risk stratification and early cancer detection. By capturing precancerous lesions and the initial molecular changes that precede overt malignancy, these atlases could transform screening practices. Early interventions informed by precise molecular maps may prevent disease progression or enable more effective, less invasive therapeutic strategies, remarkably improving patient outcomes. This proactive approach represents a paradigm shift from reactive treatment to preemptive cancer management.

The tumor microenvironment is another critical aspect illuminated by 3D atlases. Immune cells infiltrate tumors in heterogeneous patterns, with spatial distributions affecting immune evasion and responses to immunotherapy. Mapping these spatial immune landscapes at high resolution allows for a better understanding of immunological “cold” and “hot” tumors, thereby guiding the design and optimization of immunotherapeutic regimens. As immunotherapies become increasingly central to oncology, spatial multi-omics provides a valuable framework for personalizing treatment.

Beyond immune cells, cancer-associated fibroblasts (CAFs) and other stromal components play multifaceted roles in tumor progression and therapy resistance. The structural and functional mapping of CAF subpopulations unveils their diverse contributions within tumor niches. Three-dimensional atlases facilitate the spatial localization of these subpopulations alongside tumor cells, revealing patterns of influence on tumor architecture and therapy responses. Targeting specific stromal components identified in spatial contexts could enhance therapeutic efficacy and overcome resistance mechanisms.

Metastasis—the deadly hallmark of cancer—also gains new investigative tools through 3D spatial omics. By charting the molecular evolution and spatial dissemination of metastatic clones from primary tumors across multiple sites, these atlases delineate the trajectories and mechanisms of cancer spread. Understanding how metastatic niches establish and thrive within distinct tissue microenvironments opens possibilities for intercepting metastasis at early stages, potentially reducing mortality rates associated with late-stage cancer.

The construction of these atlases is bolstered by novel technological platforms, including high-resolution imaging mass cytometry, spatial transcriptomics, and multiplexed immunohistochemistry. These approaches permit the simultaneous assessment of tens to hundreds of molecular markers in situ, preserving spatial contexts at single-cell or subcellular resolutions. Integration of these data types into 3D frameworks requires harmonization of disparate datasets and stringent quality controls to ensure biological validity. Interdisciplinary collaborations among biologists, engineers, and data scientists are therefore crucial to pushing the frontiers of this field.

As these technological horizons expand, so do the challenges associated with clinical translation. Incorporating spatial multi-omics into routine diagnostics involves scaling these complex assays, reducing costs, and ensuring reproducibility and clinical relevance. Robust computational pipelines capable of delivering actionable insights within clinically acceptable timelines are essential. Furthermore, ethical considerations regarding patient data privacy and consent for extensive molecular profiling remain paramount and warrant diligent attention.

The potential impact of 3D multi-omics tumor atlases extends beyond immediate clinical applications, offering new avenues for fundamental cancer research. By providing a spatially resolved molecular atlas of tumor ecosystems, researchers can investigate the fundamental mechanisms driving tumor heterogeneity and resistance evolution. Such insights can unveil novel therapeutic targets that disrupt critical tumor-microenvironment interactions, ultimately fostering innovative drug development strategies.

In sum, the advent of 3D multi-omics tumor atlases represents a transformative leap forward in oncology, bridging the gap between molecular detail and spatial context across tumor ecosystems. These atlases integrate high-dimensional data across multiple scales, from molecular to cellular to tissue architectures, and capture temporal tumor dynamics in unprecedented detail. Their capacity to elucidate the complexity of tumor biology promises revolutionary advances in early detection, personalized therapy, and ultimately, cancer prevention.

As this field continues to unfold, the synergy of cutting-edge technologies, computational innovations, and clinical aspirations will shape a future where cancer interception becomes both precise and proactive. The path forward entails refining atlas generation, enhancing accessibility, and fostering collaborative networks that accelerate translation from bench to bedside. This holistic approach, empowered by spatial multi-omics, may finally tip the scales in favor of patients in the ongoing war against cancer.

Subject of Research: Development and application of three-dimensional spatial multi-omics tumor atlases to understand tumor heterogeneity, evolution, and clinical translation.

Article Title: 3D multi-omics tumour atlases: from technology to biology and clinical translation.

Article References:
Liu, M., Villazon, J., Forjaz, A. et al. 3D multi-omics tumour atlases: from technology to biology and clinical translation. Nat Rev Cancer (2026). https://doi.org/10.1038/s41568-026-00940-0

Image Credits: AI Generated

Traditionally, oncologists have relied heavily on tissue biopsies to study tumors, capturing static snapshots of cancer cells alongside their immediate healthy neighbors. These biopsies provide vital genetic information, but the invasive nature and temporal limitations restrict frequent monitoring. Moreover, tumor microenvironments are dynamic, continually evolving during disease progression and in response to treatments. The inability to observe these changes in real-time has hindered precision medicine efforts, often leaving clinicians to guess how tumors might adapt or resist therapies.

The Stanford and Mayo Clinic teams tackled this challenge by integrating cutting-edge machine learning algorithms with detailed molecular profiling. Central to their approach are two computational tools—CytoSPACE and Spatial EcoTyper—which piece together spatial maps of cellular neighborhoods within tumors based on gene expression patterns. CytoSPACE, developed just last year, accurately assigns individual cells to their precise coordinates within tumor tissue, akin to plotting every resident on a detailed city map. Spatial EcoTyper complements this by characterizing cell types, states, and interactions, revealing distinct spatial ecotypes—cellular communities with unique genetic and functional signatures.

By applying these methods to over 100 tumor samples spanning ten diverse cancer types, the researchers identified nine conserved spatial ecotypes within tumors, regardless of cancer origin. These cellular neighborhoods varied in location and composition, some residing at interfaces between tumor and healthy tissue, others deep within malignant masses. Crucially, certain ecotypes correlated strongly with patients’ responses to immunotherapy, suggesting these spatial patterns could serve as biomarkers guiding personalized treatment choices.

A critical insight emerged when the team observed that individual immune cells like CD8 T cells displayed context-dependent gene expression profiles influenced by their surrounding cellular “neighbors.” This discovery parallels human social behavior—distinct conversations and interactions occurring in different social settings despite the presence of common participants. In the tumor microenvironment, these spatially dependent gene expression programs define the functional states of cells, potentially tipping the balance between tumor suppression and progression.

Recognizing the clinical constraints of repeated biopsies, the scientists sought a less invasive method to capture these spatial relationships. Their solution lies in analyzing methylation patterns—chemical modifications on DNA that reflect gene expression activities—in circulating cell-free DNA found in patients’ blood. Tumors and surrounding cells release fragments of their DNA into the bloodstream upon cell death, carrying methylation “signatures” indicative of their origins and current states. Leveraging artificial intelligence, the team developed Liquid EcoTyper, a tool capable of reconstructing the tumor microenvironment from these methylation signals, effectively translating blood samples into dynamic maps of spatial ecotypes.

Validation studies demonstrated strong concordance between spatial ecotype profiles derived from tumor biopsies and those inferred via Liquid EcoTyper from patient blood samples. This breakthrough paves the way for longitudinal monitoring of tumor ecosystems through simple blood draws, enabling clinicians to track the evolving interactions within the tumor microenvironment as patients undergo therapy. Such real-time insights could alert physicians to emerging resistance mechanisms or shifts in immune landscapes, prompting timely adjustments to treatment regimens.

Beyond its diagnostic potential, this research challenges the tumor-centric paradigm that has dominated cancer biology. By highlighting the pivotal roles played by surrounding healthy cells—including fibroblasts, immune modulators, and vascular elements—in shaping tumor behavior, the study underscores the importance of targeting the tumor microenvironment alongside malignant cells. This holistic perspective promises novel therapeutic avenues that disrupt the nurturing niches fostering cancer growth.

Mechanistically, cancer cells employ sophisticated strategies to co-opt their neighbors. They induce blood vessel formation (angiogenesis) to secure vital nutrients, reprogram immune cells to evade detection, and stimulate fibroblasts to generate collagen-rich scaffolds that shield tumors from immune attack. Each spatial ecotype represents a unique micro-ecosystem wherein these interactions unfold, orchestrating cancer progression and influencing therapeutic success. By mapping these ecotypes, Liquid EcoTyper offers a window into the molecular conversations driving malignancy.

The implications for immunotherapy are particularly profound. Immunotherapies, which unleash the immune system against cancer, often exhibit variable efficacy across patients with seemingly similar tumors. This variability may stem from differences in spatial ecotypes within tumors that modulate immune cell activation and infiltration. Liquid EcoTyper’s ability to noninvasively detect ecotype patterns associated with favorable immunotherapy responses heralds a new era of predictive and adaptive cancer care.

Looking ahead, the researchers envision integrating liquid biopsy-based spatial profiling into clinical workflows, furnishing oncologists with actionable intelligence throughout the treatment journey. Repeated assessments could refine individualized therapy plans, minimize unnecessary toxicities, and ultimately improve survival outcomes. Before widespread adoption, however, comprehensive clinical trials will be necessary to validate Liquid EcoTyper across broader patient populations and cancer subtypes.

The study represents a remarkable convergence of biomedical data science, genomics, and computational biology. It exemplifies how sophisticated algorithms can extract meaningful biological signals from high-dimensional data, transforming clinical diagnostics and deepening our understanding of tumor ecosystems. Fueled by collaborative efforts spanning prestigious institutions, the research underscores the growing importance of interdisciplinary approaches in tackling cancer’s complexity.

While significant challenges remain, such as standardizing assay protocols and ensuring robust interpretation in diverse clinical contexts, the demonstration of a blood test that noninvasively captures spatial ecotypes marks a paradigm shift in oncology. It opens avenues for exploring tumor ecology dynamically and noninvasively, moving beyond static snapshots toward continuous monitoring and precise intervention.

In essence, this innovative methodology reframes cancer not as a solitary invader but as a thriving community embedded within a complex cellular milieu. Understanding and disrupting these malignant neighborhoods may prove pivotal to defeating one of humanity’s deadliest foes. As the field moves forward, tools like Liquid EcoTyper promise to empower clinicians with unprecedented clarity into the tumor microenvironment’s spatial and functional architecture, heralding a future where cancer treatment is smarter, more adaptive, and profoundly personalized.

Subject of Research: Cells

Article Title: Non-invasive profiling of the tumour microenvironment with spatial ecotypes

News Publication Date: 6-May-2026

Web References:

• https://www.nature.com/articles/s41586-026-10452-4

References:

• Newman, A., et al. (2026). Non-invasive profiling of the tumour microenvironment with spatial ecotypes. Nature. DOI: 10.1038/s41586-026-10452-4

Keywords: Tumor cells, Cancer immunotherapy

Colorectal cancer remains one of the most prevalent and lethal malignancies worldwide. Among its subtypes, microsatellite instability-high (MSI-H) tumors, characterized by deficient mismatch repair mechanisms, have shown remarkable responses to immune checkpoint inhibitors. Conversely, MSS tumors constitute the majority of mCRC cases and notoriously exhibit resistance to such therapies, underscoring an urgent need for novel predictive markers and combination treatment strategies. The latest findings offer critical insights by transcending conventional genomic and transcriptomic profiling to incorporate spatial context into the tumor immune landscape.

The study employs advanced spatial transcriptomics and multiplex immunofluorescence imaging techniques to interrogate the intricate cellular architecture within the tumor microenvironment of MSS mCRC patients undergoing chemo-immunotherapy. By meticulously analyzing spatial patterns of immune cells, stromal components, and tumor cells, the researchers have identified distinct topographical niches that correlate with therapeutic response. This approach marks a paradigm shift, emphasizing that the mere presence or absence of immune cells is insufficient without considering their spatial distribution and interaction dynamics.

One of the salient revelations from the study is the identification of immune-enriched regions within the tumor periphery that serve as robust indicators of positive response to combination chemotherapeutic and immunotherapeutic regimens. These niches exhibit a high density of cytotoxic T lymphocytes (CTLs) interspersed with antigen-presenting cells, fostering an immunologically active milieu conducive to tumor eradication. Conversely, tumors devoid of such spatially organized immune clusters tended to exhibit resistance, highlighting the prognostic value of spatial immune profiling.

Furthermore, the research delineates how stromal elements, particularly cancer-associated fibroblasts (CAFs), sculpt immune cell localization and function through extracellular matrix remodeling and secretion of immunomodulatory factors. The spatial interplay between CAFs and immune infiltrates emerged as a determinant of immunotherapy responsiveness, suggesting that targeting stromal components might potentiate therapeutic outcomes in MSS mCRC.

The integration of spatial transcriptomic data with clinical response metrics allowed the construction of predictive models capable of stratifying MSS mCRC patients based on their likelihood of benefiting from chemo-immunotherapy. These models incorporate spatial gene expression signatures, immune cell localization indices, and stromal interaction patterns, offering unprecedented precision in forecasting treatment success. Such advances hold promise for guiding personalized therapeutic strategies and circumventing the trial-and-error approach that remains pervasive in oncology.

Importantly, the study also sheds light on the temporal evolution of the tumor microenvironment under therapeutic pressure. Longitudinal spatial analysis revealed dynamic remodeling of immune niches, with responders exhibiting sustained immune cell infiltration and activation, while non-responders manifested progressive immune exclusion. This temporal dimension underscores the importance of monitoring spatial biomarkers not merely at baseline but throughout the treatment course to inform adaptive therapeutic interventions.

Mechanistically, the findings implicate key molecular pathways underpinning spatial immune organization, including chemokine-mediated recruitment and retention of CTLs, and signaling circuits modulating stromal-immune crosstalk. Targeting these pathways could unlock new avenues to convert immunologically ‘cold’ MSS tumors into ‘hot’ responsive ones, thus broadening the spectrum of patients amenable to immunotherapy.

The ramifications of this study extend beyond MSS mCRC, providing a conceptual framework applicable to other malignancies where spatial heterogeneity dictates therapeutic response. By leveraging cutting-edge spatial omics technologies, oncologists and researchers can unravel the complex ecosystem of tumors with unprecedented granularity, facilitating the design of next-generation combination therapies tailored to spatial biomarker profiles.

This research heralds a new era in precision oncology, where the spatial dimension of the tumor microenvironment is recognized as a critical determinant of cancer immunotherapy success. The ability to map, quantify, and manipulate spatial immune landscapes may ultimately overcome resistance barriers and improve survival outcomes for patients with MSS metastatic colorectal cancer and potentially other treatment-resistant cancers.

As these insights translate into clinical practice, we can anticipate the development of novel diagnostic assays incorporating spatial biomarker panels to select patients for chemo-immunotherapy. Moreover, therapeutic strategies integrating agents that modulate tumor architecture and immune cell positioning could synergize with existing treatments, enhancing efficacy and minimizing adverse effects.

The discovery also galvanizes further exploration into spatial biology, stimulating interdisciplinary collaborations among oncologists, immunologists, bioinformaticians, and imaging specialists. Such concerted efforts are vital to harness the full potential of spatially resolved data and to innovate therapeutic interventions that are both biologically rational and clinically impactful.

In summary, the study by Choo, Zhao, Lau, and colleagues articulately demonstrates that spatial predictors within the tumor microenvironment hold the key to unlocking effective chemo-immunotherapy in microsatellite stable metastatic colorectal cancer. It challenges the oncology community to rethink current paradigms and embrace spatial complexity as a cornerstone of personalized cancer treatment.

As this field rapidly evolves, ongoing clinical trials incorporating spatial profiling will be instrumental in validating these predictive markers and translating them into standardized protocols. The convergence of spatial biology with immuno-oncology stands to revolutionize how we understand, diagnose, and treat cancers that have long eluded durable control.

This pioneering work illuminates a path forward, inspiring hope that meticulously decoding the spatial language of tumors will yield transformative therapies for patients who urgently need them. The quest continues to delineate the full spectrum of spatial determinants governing immune responsiveness, heralding an era where the architecture of tumors informs the architecture of cure.

Subject of Research: Spatial Predictors of Response to Chemo-immunotherapy in Microsatellite Stable Metastatic Colorectal Cancer

Article Title: Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer

Article References:

Choo, J., Zhao, J.J., Lau, M.C. et al. Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer.
Nat Commun (2026). https://doi.org/10.1038/s41467-026-72204-2

Image Credits: AI Generated

Tumors are no longer viewed as mere clusters of malignant cells but as complex ecosystems. The intricate interplay between cancer cells, immune cells, fibroblasts, and surrounding extracellular matrix (ECM) literally shapes disease progression and treatment responses. While traditional pathology protocols offered two-dimensional snapshots often limited to histological staining, this research leverages high-resolution single-cell spatial technologies, offering a multidimensional and molecularly precise view of tumor architecture with cellular neighborhood resolution.

Central to this advancement is the application of spatial transcriptomics, a technology that profiles RNA expression with remarkable spatial context. Unlike conventional transcriptomics, which bulk-analyzes RNA from homogenized tissue samples, spatial transcriptomics preserves the positional information of transcripts at single-cell resolution. Employing the innovative CosMx platform by NanoString, Rajewsky’s team was able to detect up to 1,000 distinct RNA molecules per cell, a quantum leap from earlier methods constrained to just a few markers. This enabled detailed profiling of over 340,000 individual cells, encompassing 18 distinct cell types within a single lung tumor, highlighting the heterogeneous cellular milieu.

However, the leap from two-dimensional to three-dimensional analysis required innovative computational solutions. The team introduced STIM, a novel algorithm designed to reconstruct 3D virtual tissue blocks by aligning multiple spatial transcriptomic datasets. STIM conceptualizes spatial transcriptomic data as digital images, applying computer vision techniques to stack and align these images, culminating in a holistic 3D tissue reconstruction. This integration underscores the power of interdisciplinary collaboration, merging computational sciences with molecular biology, and was further enhanced by expertise from Dr. Stephan Preibisch at the Howard Hughes Medical Institute.

The 3D reconstructions revealed more than just cellular identities: by coupling these maps with second harmonic generation imaging, the researchers visualized key ECM components, including elastin and collagen fibers. This dual-layered imaging disclosed spatial variations in ECM composition, where elastin-rich regions correlated with healthier tissue, whereas areas rich in collagen congregated around the tumor core, signifying deleterious tissue remodeling driven by the tumor microenvironment. Such details illuminate how structural alterations to the ECM contribute to cancer progression.

Crucially, this approach illuminated dynamic cellular interactions within the tumor. Fibroblasts, cells responsible for synthesizing connective tissue, were observed in activated states remodeling the ECM, creating a scaffold supporting tumor growth. Beyond static snapshots, the data unveiled functional phenotypes and intercellular signaling, particularly mechanisms by which tumor cells suppress infiltration of immune cells. The findings emphasized the presence of immune niches surrounding the tumor core that, despite their proximity, were functionally impaired due to tumor-induced immunosuppression.

Understanding the precise molecular crosstalk that underpins immune evasion is vital. The study exposes how tumors can inhibit immune cell penetration through known checkpoint pathways, validating immunotherapy strategies that employ immune checkpoint inhibitors. By reversing this localized immune suppression, such therapies could unleash resident immune cells that are otherwise incapacitated, offering a personalized treatment strategy that conventional chemotherapy alone could not provide.

What sets this research apart is its applicability to routine clinical samples. Despite utilizing sophisticated molecular techniques, the team demonstrated that archived formalin-fixed, paraffin-embedded (FFPE) tissue sections—commonly preserved in clinical pathology labs—are amenable to this high-resolution analysis. This “Pathology 2.0” approach transcends traditional microscopy, enriching pathological examination with molecular and spatial depth, and has the potential to transform diagnostic and therapeutic decision-making in oncology.

The translational promise of this integrated spatial approach is monumental. By comprehensively mapping cellular neighborhoods and molecular signals within tumors, physicians could tailor immunotherapies and other interventions with unprecedented precision. Moreover, expanding these techniques to larger patient cohorts is underway, with ongoing analyses involving hundreds of additional samples. Such scaling will enable validation of molecular targets and foster development of broadly applicable personalized medicine protocols.

Another frontier being explored involves integrating proteomic data into the comprehensive tissue map. Collaborations with Dr. Fabian Coscia’s Spatial Proteomics Lab at MDC aim to incorporate protein activity measurements alongside RNA expression and ECM imaging. This multi-omic synergy will deepen insights into functional tumor biology, elucidate post-transcriptional regulation, and refine therapeutic target identification.

This study represents a paradigm shift in cancer research and diagnostics. By synergizing single-cell resolution spatial transcriptomics with advanced ECM imaging and novel computational reconstructions, researchers can now dissect the tumor microenvironment with molecular and spatial fidelity previously unattainable. The resulting data describe not only who is present in the tumor but where, how, and why they interact – all essential information for designing personalized therapies capable of halting tumor progression and improving patient outcomes.

Professor Rajewsky encapsulates the significance succinctly: the comprehensive data from patient tumor tissues now allow computational predictions of the molecular mechanisms driving cancer phenotypes. This predictive capacity could revolutionize oncology, moving from generalized treatments toward truly individualized interventions—a vision for precision medicine now within reach.

In essence, the collaboration between biology, computational science, and advanced imaging heralds a new era where high-tech analytical tools refine routine pathology into a powerful platform for personalized cancer care. The integration of spatial, molecular, and functional data sets a foundation for next-generation diagnostics and therapeutics, promising hope for patients facing lung cancer and other malignancies. With further validation and clinical application, these innovations will likely redefine cancer management strategies over the coming decade.

—

Subject of Research: Cells

Article Title: Combining spatial transcriptomics and ECM imaging in 3D for mapping cellular interactions in the tumor microenvironment

News Publication Date: 11-Apr-2025

Web References: 10.1016/j.cels.2025.101261

Image Credits: Rajewsky lab, Max Delbrück Center

Keywords: spatial transcriptomics, 3D tumor mapping, extracellular matrix imaging, single-cell analysis, lung cancer, tumor microenvironment, immunotherapy, computational modeling, personalized medicine